

Applicants: Philip O. Livingston and Friedhelm Helling
Serial No.: 08/196,154
Filed : November 16, 1995
Page 2

wherein the deleted material is in brackets and the inserted material is underlined is attached hereto as Exhibit A:

G¹
Am
H1

--97. (Amended) A composition which comprises:
a) a conjugate of i) a GM2 or GD2 ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising a sphingosine base, to ii) Keyhole Limpet Hemocyanin comprising an ϵ -aminolysyl group;
b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and
c) a pharmaceutically acceptable carrier;
the relative amounts of such conjugate and such saponin being effective to stimulate or enhance antibody production in a subject,
wherein in the conjugate the ganglioside derivative is conjugated to Keyhole Limpet Hemocyanin through a C-4 carbon of the sphingosine base of the ceramide portion of the ganglioside derivative to the ϵ -aminolysyl group of Keyhole Limpet Hemocyanin.--

G²
Am
H2 >

--110. (Amended) The composition of claim 97, wherein the molar ratio of the ganglioside derivative to Keyhole Limpet Hemocyanin is between about 200 and about 1400.--

--111. (Amended) A method of stimulating or enhancing antibody production in a subject which comprises administering to the subject an effective amount of a composition which comprises:

Applicants: Philip O. Livingston and Friedhelm Helling
Serial No.: 08/196,154
Filed : November 16, 1995
Page 3

- Ans*
G2 H2
uf
- a) a conjugate of i) a GM2 or GD2 ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising a sphingosine base, to ii) Keyhole Limpet Hemocyanin comprising an ϵ -aminolysyl group;
- b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and
- c) a pharmaceutically acceptable carrier;
- the relative amounts of such conjugate and such saponin being effective to stimulate or enhance antibody production in the subject, wherein in the conjugate the ganglioside derivative is conjugated to Keyhole Limpet Hemocyanin through a C-4 carbon of the sphingosine base of the ceramide portion of the ganglioside derivative to the ϵ -aminolysyl group of Keyhole Limpet Hemocyanin, so as to thereby stimulate or enhance antibody production in the subject.--
-

--113. (Amended) A method of treating a cancer in a subject which comprises administering to the subject an effective cancer treating amount of a composition which comprises:

- G4*
Ans
H3
- a) a conjugate of i) a GM2 or GD2 ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising a sphingosine base, to ii) Keyhole Limpet Hemocyanin comprising an ϵ -aminolysyl group;
- b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and

Applicants: Philip O. Livingston and Friedhelm Helling
U.S. Serial No.:08/196,154
Filed: November 16, 1995
Page:4

Ans
A3
G4
c) a pharmaceutically acceptable carrier;
the relative amounts of such conjugate and such saponin
being effective to stimulate or enhance antibody
production in the subject,
wherein in the conjugate the ganglioside derivative is
conjugated to Keyhole Limpet Hemocyanin through a C-4
carbon of the sphingosine base of the ceramide portion of
the ganglioside derivative to the ϵ -aminolysyl group of
Keyhole Limpet Hemocyanin, so as to thereby treat the
cancer in the subject.--

G5
--114. (Amended) The method of claim 113, wherein the cancer is
of epithelial origin.--

G6
--115. (Amended) The method of claim 113, wherein the cancer is
of neuroectodermal origin.--

--117. (Amended) The method of claim 111 or 113, wherein the
administering is effected at two or more sites.--

REMARKS

Claims 97-118 are pending in the subject application. Applicants
have hereinabove canceled claims 100 and 112 without disclaimer or
prejudice to applicants' right to pursue the subject matter of this
claim in a later-filed application and amended claims 97, 110-111,
113-115 and 117. This amendment does not involve any issue of new
matter. Therefore, entry of this amendment is respectfully
requested such that claims 97-99, 101-111 and 113-118 will be
pending.